See more : Anew Medical, Inc. (WENA) Income Statement Analysis – Financial Results
Complete financial analysis of Kadimastem Ltd (KMSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kadimastem Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Text S.A. (TXT.WA) Income Statement Analysis – Financial Results
- Charwood Energy SA (ALCWE.PA) Income Statement Analysis – Financial Results
- LGBTQ Loyalty Holdings, Inc. (LFAP) Income Statement Analysis – Financial Results
- Surge Copper Corp. (SRGXF) Income Statement Analysis – Financial Results
- Bonesupport Holding AB (publ) (2B4.F) Income Statement Analysis – Financial Results
Kadimastem Ltd (KMSTF)
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 684.00K | 1.70M | 1.03M | 323.00K | 240.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.00K | 134.00K | 106.00K | 70.00K | 100.00K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 636.00K | 1.57M | 922.00K | 253.00K | 140.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.98% | 92.13% | 89.69% | 78.33% | 58.33% | 0.00% |
| Research & Development | 7.81M | 15.08M | 17.12M | 13.25M | 17.82M | 16.65M | 14.87M | 13.09M | 9.61M | 8.52M | 7.84M | 11.74K |
| General & Administrative | 4.81M | 1.82M | 2.11M | 2.98M | 2.41M | 1.88M | 2.02M | 2.33M | 1.57M | 1.68M | 1.38M | 2.37K |
| Selling & Marketing | 300.00K | 299.00K | 450.00K | 211.00K | 291.00K | 521.00K | 183.00K | 301.00K | 260.00K | 140.00K | 220.00K | 239.00 |
| SG&A | 5.11M | 2.11M | 2.56M | 3.19M | 2.70M | 2.40M | 2.20M | 2.63M | 1.83M | 1.82M | 1.60M | 2.61K |
| Other Expenses | -1.87M | 4.82M | 4.62M | 3.85M | 4.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.04M | 22.01M | 24.30M | 20.29M | 24.71M | 23.62M | 21.47M | 20.94M | 16.34M | 15.83M | 15.29M | 10.01K |
| Cost & Expenses | 11.04M | 22.01M | 24.30M | 20.29M | 24.71M | 23.62M | 21.52M | 21.07M | 16.45M | 15.90M | 15.39M | 10.01K |
| Interest Income | 392.00K | 47.00K | 462.00 | 15.00K | 27.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 93.00 |
| Interest Expense | 0.00 | 252.00K | 394.00K | 469.00K | 156.00K | 78.00K | 0.00 | 0.00 | 0.00 | 0.00 | 61.00K | 0.00 |
| Depreciation & Amortization | 384.00K | 1.94M | 1.85M | 1.82M | 1.08M | 433.00K | 665.00K | 756.00K | 774.00K | 732.00K | 649.00K | 650.00 |
| EBITDA | -10.66M | -20.69M | -24.48M | -19.68M | -24.04M | -23.18M | -20.17M | -18.61M | -14.65M | -14.85M | -14.50M | -10.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,949.12% | -1,092.95% | -1,338.62% | -4,813.93% | -7,023.75% | 0.00% |
| Operating Income | -11.04M | -22.01M | -24.30M | -20.29M | -24.71M | -23.62M | -20.84M | -19.37M | -15.42M | -15.58M | -15.15M | -11.05K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,046.35% | -1,137.35% | -1,500.10% | -4,823.53% | -6,311.67% | 0.00% |
| Total Other Income/Expenses | -1.17M | -875.00K | -2.42M | -1.68M | -567.00K | -403.00K | -766.00K | -748.00K | -1.80M | 229.00K | 2.40M | 945.00 |
| Income Before Tax | -12.21M | -22.89M | -26.72M | -21.96M | -25.27M | -24.02M | -21.60M | -20.12M | -17.22M | -15.35M | -12.75M | -10.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,158.33% | -1,181.27% | -1,675.39% | -4,752.63% | -5,312.50% | 0.00% |
| Income Tax Expense | 200.00K | -167.00K | -443.00K | -253.00K | -186.00K | -51.00K | -175.00K | -144.00K | -159.00K | -160.00K | -136.00K | 52.00 |
| Net Income | -12.05M | -22.72M | -26.28M | -21.71M | -25.09M | -23.97M | -21.43M | -19.97M | -17.06M | -15.19M | -12.61M | -10.05K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,132.75% | -1,172.81% | -1,659.92% | -4,703.10% | -5,255.83% | 0.00% |
| EPS | -2.80 | -6.50 | -84.70 | -117.70 | -185.50 | -309.30 | -446.40 | -920.40 | -940.20 | -986.40 | -970.30 | -0.11 |
| EPS Diluted | -2.80 | -6.50 | -84.70 | -117.70 | -185.40 | -309.20 | -445.80 | -918.50 | -940.00 | -983.10 | -964.40 | -0.11 |
| Weighted Avg Shares Out | 4.24M | 3.49M | 310.20K | 184.45K | 135.25K | 77.50K | 48.00K | 21.70K | 18.15K | 15.40K | 13.00K | 92.20K |
| Weighted Avg Shares Out (Dil) | 4.24M | 3.49M | 310.28K | 184.52K | 135.32K | 77.51K | 48.07K | 21.75K | 18.15K | 15.45K | 13.08K | 92.28K |
Source: https://incomestatements.info
Category: Stock Reports